Clinical Overview of Enfortumab Vedotin in the Management of Locally Advanced or Metastatic Urothelial Carcinoma-Reference-Cited by-同舟云学术

Clinical Overview of Enfortumab Vedotin in the Management of Locally Advanced or Metastatic Urothelial Carcinoma

Published:2019-12-10 Issue:1 Volume:80 Page:1-7
ISSN:0012-6667
Container-title:Drugs
language:en
Short-container-title:Drugs

Author:

Hanna Kirollos S.^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical)

Link

http://link.springer.com/content/pdf/10.1007/s40265-019-01241-7.pdf

Reference28 articles.

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7–34.

2. NCCN. The NCCN Clinical Practical Guidelines in Oncology Bladder Cancer (Version 3.2019). 2019; http://www.nccn.org/professionals/physician_gls/pdf/bladder.pdf. Accessed 30 July 2019.

3. National Cancer Institute. SEER stat fact sheets: Bladder cancer. 2019. https://seer.cancer.gov/statfacts/html/urinb.html. Accessed 30 July 2019.

4. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature. 2014;507(7492):315–22.

5. Balversa (erdafitinib) [prescribing information]. Horsham, PA: Janssen Products; April 2019.

Cited by 39 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Nectin-4-directed antibody-drug conjugates (ADCs): Spotlight on preclinical and clinical evidence;Life Sciences;2024-09

2. Post-marketing drug safety surveillance of enfortumab vedotin: an observational pharmacovigilance study based on a real-world database;Frontiers in Immunology;2024-08-20

3. Antibody-drug conjugates in solid tumors; new strategy for cancer therapy;Japanese Journal of Clinical Oncology;2024-05-04

4. Peptide Therapeutics: Unveiling the Potential against Cancer—A Journey through 1989;Cancers;2024-03-02

5. WDR4 promotes the progression and lymphatic metastasis of bladder cancer via transcriptional down-regulation of ARRB2;Oncogenesis;2023-10-02